Last reviewed · How we verify
Ciprofloxacin Ophthalmic
At a glance
| Generic name | Ciprofloxacin Ophthalmic |
|---|---|
| Sponsor | Medical University of Vienna |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Antibiotic Eye Drops on the Nasal Microbiome in Healthy Subjects (PHASE2)
- Evaluation of Efficacy and Safety of Topical 1% Medroxyprogesterone in the Corneal Epithelium Healing After PRK (PHASE2, PHASE3)
- 3Mixtatin Versus Modified 3Mix-MP in Lesion Sterilization and Tissue Repair for Treatment of Necrotic Primary Molars (NA)
- Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial (PHASE2)
- Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (PHASE3)
- Evaluation of Treatment Option for Demodicosis in Patients Undergoing Cataract Surgery (PHASE2, PHASE3)
- Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects (PHASE1)
- Focal Laser Ablation for Benign Prostatic Hyperplasia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciprofloxacin Ophthalmic CI brief — competitive landscape report
- Ciprofloxacin Ophthalmic updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI